JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

Search

Quidel Corp

Închisă

11.61 3.57

Rezumat

Modificarea prețului

24h

Curent

Minim

11.41

Maxim

11.61

Indicatori cheie

By Trading Economics

Venit

602M

-131M

Vânzări

24M

724M

Marjă de profit

-18.062

Angajați

6,500

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+78.34% upside

Dividende

By Dow Jones

Următoarele câștiguri

5 mai 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-483M

726M

Deschiderea anterioară

8.04

Închiderea anterioară

11.61

Quidel Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

24 apr. 2026, 19:19 UTC

Achiziții, Fuziuni, Preluări

Intertek Group Rejects EQT's Revised Offer

24 apr. 2026, 23:37 UTC

Achiziții, Fuziuni, Preluări

Scoring the Cook Era -- Barrons.com

24 apr. 2026, 20:51 UTC

Achiziții, Fuziuni, Preluări

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr. 2026, 20:50 UTC

Market Talk
Evenimente importante

Financial Services Roundup: Market Talk

24 apr. 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

24 apr. 2026, 20:39 UTC

Achiziții, Fuziuni, Preluări

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr. 2026, 20:09 UTC

Câștiguri

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24 apr. 2026, 19:48 UTC

Market Talk
Evenimente importante

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24 apr. 2026, 19:25 UTC

Achiziții, Fuziuni, Preluări

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr. 2026, 19:25 UTC

Achiziții, Fuziuni, Preluări

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24 apr. 2026, 19:22 UTC

Câștiguri

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24 apr. 2026, 19:06 UTC

Câștiguri

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24 apr. 2026, 19:05 UTC

Market Talk

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24 apr. 2026, 18:30 UTC

Achiziții, Fuziuni, Preluări

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24 apr. 2026, 18:28 UTC

Achiziții, Fuziuni, Preluări

Intertek Rejects Revised EQT Offer

24 apr. 2026, 18:12 UTC

Market Talk

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24 apr. 2026, 18:06 UTC

Market Talk

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24 apr. 2026, 17:42 UTC

Câștiguri

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24 apr. 2026, 17:28 UTC

Câștiguri

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

24 apr. 2026, 17:28 UTC

Market Talk

Crypto Fear and Greed Index Slides Back to Neutral -- Market Talk

24 apr. 2026, 17:12 UTC

Market Talk

Global Equities Roundup: Market Talk

24 apr. 2026, 17:11 UTC

Market Talk

Apple Seen Gaining Market Share Despite Memory Crunch -- Market Talk

24 apr. 2026, 17:09 UTC

Market Talk
Câștiguri

Intel Seen With Stronger Long-Term Earnings Power -- Market Talk

24 apr. 2026, 17:09 UTC

Achiziții, Fuziuni, Preluări

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr. 2026, 17:06 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Correction to Advanced Micro Devices Stock Gets Upgraded to Buy. Why It's the Big Winner of Intel Earnings. -- Barrons.com

24 apr. 2026, 16:51 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Two Big Loan Defaults Add to Pain in Private-Credit Funds -- WSJ

24 apr. 2026, 16:20 UTC

Market Talk
Câștiguri

Tech, Media & Telecom Roundup: Market Talk

24 apr. 2026, 16:20 UTC

Market Talk
Evenimente importante

Financial Services Roundup: Market Talk

24 apr. 2026, 16:20 UTC

Market Talk
Câștiguri

Auto & Transport Roundup: Market Talk

24 apr. 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

Comparație

Modificare preț

Quidel Corp Așteptări

Obiectiv de preț

By TipRanks

78.34% sus

Prognoză pe 12 luni

Medie 20.67 USD  78.34%

Maxim 30 USD

Minim 15 USD

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruQuidel Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

5 ratings

1

Cumpărare

3

Păstrare

1

Vânzare

Date financiare

Cheltuieli de vânzare și administrare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

Profit operațional

$

Despre Quidel Corp

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
help-icon Live chat